Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Ostrava – page 2

285 clinical trials in Ostrava, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Ostrava at a glance
285
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

285 trials in Ostrava

Open in trial search

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Desloratadine
  • Sponsor:Allergy Therapeutics (UK) Limited

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Etentamig
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Ostrava

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer and lung cancer treatments. Studies include evaluation of novel therapies for multiple myeloma and various forms of leukemia.

  • Prostate Cancer Treatment Advances
  • Small Cell Lung Cancer Therapy
  • Blood Cancer Interventions

Multiple collaborative studies exploring targeted therapies and combination treatments for advanced-stage cancers.

02 Immunology and Inflammatory Diseases

Research targeting inflammatory bowel diseases, including studies on Crohn's Disease and ulcerative colitis. Investigations into novel treatments for psoriatic arthritis.

  • Inflammatory Bowel Disease Management
  • Autoimmune Conditions
  • Chronic Inflammatory Disorders

Comprehensive evaluation of innovative therapeutic approaches for chronic inflammatory conditions.

03 Cardiovascular and Infectious Diseases

Studies examining cardiovascular disease treatments and prevention strategies. Research on bacterial infections and antimicrobial therapies, including trials for complicated urinary tract infections.

  • Heart Disease Prevention
  • Infection Management
  • Antibiotic Optimization

Advanced research combining preventive approaches with targeted therapeutic interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.